Cite
HARVARD Citation
Weber, J. et al. (n.d.). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet oncology. 16 (4), pp. 375-384. [Online].